Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis

References

• Hiwatari N, Shimura S, Takishima T. Pulmonary emphysema followed by pulmonary fibrosis of undetermined cause. Respiration. 1993;60(6):354–358.
   PubMed Web of Science ®Google Scholar
• Raghu G, Chen SY, Hou Q, et al. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old. Eur Respir J. 2016;48(1):179–186.
   PubMed Web of Science ®Google Scholar
• Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2(7):566–572.
   PubMed Web of Science ®Google Scholar
• Raimundo K, Chang E, Broder MS, et al. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med. 2016;16(2):2.
   PubMed Web of Science ®Google Scholar
• Collard HR, Ward AJ, Lanes S, et al. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ. 2012;15(5):829–835.
   PubMedGoogle Scholar
• Caminati A, Lonati C, Cassandro R, et al. Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue. Eur Respir Rev. 2019;28(153):190044.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Toews GB, Travis WD, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J. 2002;19(2):275–283.
   PubMed Web of Science ®Google Scholar
• King TE Jr., Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001;164(7):1171–1181.
   PubMed Web of Science ®Google Scholar
• Rudd RM, Prescott RJ, Chalmers JC, et al. Fibrosing alveolitis subcommittee of the Research Committee of the British Thoracic Society. British Thoracic Society study on cryptogenic fibrosing alveolitis: response to treatment and survival. Thorax. 2007;62(1):62–66.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Cottin V, Du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS((R)) trials. Respir Med. 2016;113:74–79.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–1087.
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–1769.
   PubMed Web of Science ®Google Scholar
• OFEV (nintedanib) capsules, for oral use [Package insert]. 2014 [cited 2022 Mar 7]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf.
   Google Scholar
• Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3–e19.
   PubMed Web of Science ®Google Scholar
• Kang J, Han M, Song JW. Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis. Sci Rep. 2020;10(1):15620.
   PubMed Web of Science ®Google Scholar
• Noor S, Nawaz S, Chaudhuri N. Real-World study analysing progression and survival of patients with idiopathic pulmonary fibrosis with preserved lung function on antifibrotic treatment. Adv Ther. 2021;38(1):268–277.
   PubMed Web of Science ®Google Scholar
• Brunnemer E, Walscher J, Tenenbaum S, et al. Real-World experience with nintedanib in patients with idiopathic pulmonary Fibrosis. Respiration. 2018;95(5):301–309.
   PubMed Web of Science ®Google Scholar
• Rivera-Ortega P, Hayton C, Blaikley J, et al. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience. Ther Adv Respir Dis. 2018;12:1753466618800618.
   Web of Science ®Google Scholar
• Hughes G, Toellner H, Morris H, et al. Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J Clin Med. 2016;5(9):78.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.
   PubMed Web of Science ®Google Scholar
• Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017;72(4):340–346.
   PubMed Web of Science ®Google Scholar
• Costabel U, Inoue Y, Richeldi L, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med. 2016;193(2):178–185.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Kolb M, Jouneau S, et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. 2020;20(1):3.
   PubMed Web of Science ®Google Scholar
• Brown KK, Flaherty KR, Cottin V, et al. Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis. Respir Med. 2019;146:42–48.
   PubMed Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68.
   PubMed Web of Science ®Google Scholar
• Maher TM, Swigris JJ, Kreuter M, et al. Identifying barriers to idiopathic pulmonary fibrosis treatment: a survey of patient and physician views. Respiration. 2018;96(6):514–524.
   PubMed Web of Science ®Google Scholar
• Maher TM, Molina-Molina M, Russell AM, et al. Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries. BMC Pulm Med. 2017;17(1):124.
   PubMed Web of Science ®Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682.
   PubMed Web of Science ®Google Scholar
• Clinical Classifications Software (CCS) for ICD-9-CM/ICD-10/CM. Rockville (MD): Agency for Healthcare Research and Quality. http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp.
   Google Scholar
• US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Medical Care. Series ID: CUUR0000SAM; 2019 [cited 2020 Nov 29]. http://data.bls.gov/cgi-bin/surveymost?cu
   Google Scholar
• Kolb M, Raghu G, Wells AU, et al. Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2018;379(18):1722–1731.
   PubMed Web of Science ®Google Scholar
• Dempsey TM, Sangaralingham LR, Yao X, et al. Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2019;200(2):168–174.
   PubMed Web of Science ®Google Scholar
• Russell AM, Adamali H, Molyneaux PL, et al. Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;194(8):989–997.
   PubMed Web of Science ®Google Scholar
• Collard HR, Richeldi L, Kim DS, et al. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J. 2017;49(5):1601339.
   PubMed Web of Science ®Google Scholar
• Kolb M, Bondue B, Pesci A, et al. Acute exacerbations of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180071.
   PubMed Web of Science ®Google Scholar
• Cottin V, Richeldi L. Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment. Eur Respir Rev. 2014;23(131):106–110.
   PubMedGoogle Scholar
• Reichmann WM, Yu YF, Macaulay D, et al. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis. BMC Pulm Med. 2015;15(1):167.
   PubMed Web of Science ®Google Scholar
• Torrisi SE, Pavone M, Vancheri A, et al. When to start and when to stop antifibrotic therapies. Eur Respir Rev. 2017;26(145):170053.
   PubMed Web of Science ®Google Scholar
• Wuyts WA, Wijsenbeek M, Bondue B, et al. Idiopathic pulmonary fibrosis: best practice in monitoring and managing a relentless fibrotic disease. Respiration. 2020;99(1):73–82.
   PubMed Web of Science ®Google Scholar
• Molina-Molina M, Aburto M, Acosta O, et al. Importance of early diagnosis and treatment in idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2018;12(7):537–539.
   PubMed Web of Science ®Google Scholar
• Maher TM, Strek ME. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respir Res. 2019;20(1):205.
   PubMed Web of Science ®Google Scholar